Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chęć oddania próbek tkanki guza do badań.
- •Potwierdzona obecność raka, który można zmierzyć lub nie.
- •Pacjenci z pewnymi zmianami genetycznymi w raku musieli przyjmować wcześniej inne leki, które nie pomogły.
- •Zgoda na udział w badaniu i przyjazd na wizyty kontrolne.
- •Zgoda na oddawanie próbek krwi do badań.
- •Ujemny test ciążowy dla osób w wieku rozrodczym.
- •Zastosowanie skutecznej metody antykoncepcji.
- •Dobry ogólny stan zdrowia pacjenta (typ 0-1 w skali ECOG).
✗ Disqualifies
- •Nie ma już naboru do grup 1 i 2.
- •Zmiany w guzach w miejscach wcześniej naświetlanych nie są uważane za mierzalne.
Simplified criteria — AI translation
Trial details
- Minimum age
- 16 Years
- Last updated (source)
- June 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Mayo Clinic in Florida
Jacksonville, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.